Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes

Zaazouee, Mohamed Sayed; Hamdallah, Aboalmagd; Helmy, Sara Kamel; Hasabo, Elfatih A.; Sayed, Ahmed Kamal; Gbreel, Mohamed Ibrahim; Elmegeed, Aya Abd; Aladwan, Hala; Elshanbary, Alaa Ahmed; Abdel-Aziz, Walid; Elshahawy, Israa Mohamed; Rabie, Shehab; Elkady, Sherouk; Ali, Ahmed Said; Ragab, Khaled Mohamed; Nourelden, Anas Zakarya

doi:10.1016/j.dsx.2022.102511

Cited by 23 publications

(16 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Being biologically active moieties, peptides possess an excellent tendency to serve as a promising carrier for targeted transport. Nowadays, PDCs have much broader applications with equivalent potency than ADCs not only in oncology but extended arms to treat diabetes, rheumatoid arthritis, and coronavirus disease 2019 (COVID-19) as targeted therapeutics. , …”

Section: Peptides For Drug Delivery Systemmentioning

confidence: 99%

“…Nowadays, PDCs have much broader applications with equivalent potency than ADCs not only in oncology but extended arms to treat diabetes, rheumatoid arthritis, and coronavirus disease 2019 (COVID-19) as targeted therapeutics. 77,78 The PDC's therapeutic mechanism of action depends on various factors such as the function of receptors, binding of a homing peptide with cell surface receptors, triggering the receptor-mediated endocytosis or drug internalization, and lysis under tumor microenvironment causes the release of cytotoxic payloads. Hence, the nature of homing peptide plays a pivotal role in determining the mechanism of action of PDCs and has a significant impact on PK/PD profile, efficacy, targeting ability, and therapeutic index.…”

Section: ■ Peptides For Drug Delivery Systemmentioning

confidence: 99%

See 1 more Smart Citation

Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic

Rizvi,

Zhang,

Zhang

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

The emergence of peptide−drug conjugates (PDCs) that utilize targetoriented peptide moieties as carriers of cytotoxic payloads, interconnected with various cleavable/noncleavable linkers, resulted in the key-foundation of the new era of targeted therapeutics. They are capable of retaining the integrity of conjugates in the blood circulatory system as well as releasing the drugs at the tumor microenvironment. Other valuable advantages are specificity and selectivity toward targeted-receptors, higher penetration ability, and drug-loading capacity, making them a suitable candidate to play their vital role as promising carrier agents. In this review, we summarized the types of cell-targeting (CTPs) and cell-penetrating peptides (CPPs) that have broad applications in the advancement of targeted drug-delivery systems (DDS). Moreover, the techniques to overcome the limitations of peptide-chemistry for their extensive implementation to construct the PDCs. Besides this, the diversified breakthrough of linker chemistry, and ample knowledge of various cytotoxic payloads used in PDCs in recent years, as well as the mechanism of action of PDCs was critically discussed. The principal aim is to provide scattered and diversified knowledge in one place and to help researchers understand the pinching knots in the science of PDC development, also their progression toward a bright future for PDCs as novel theranostics in clinical practice.

show abstract

Section: Peptides For Drug Delivery Systemmentioning

confidence: 99%

Section: ■ Peptides For Drug Delivery Systemmentioning

confidence: 99%

Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic

Rizvi,

Zhang,

Zhang

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

show abstract

“…Potentiation of side effects has not been observed with oral triple combination; they are essentially the same as those observed with monotherapy for the respective substance. A new option is the combination of a “classic” oral antidiabetic drug with semaglutide orally 75 76 77 78 .…”

Section: Therapymentioning

confidence: 99%

Therapy of Type 2 Diabetes

Landgraf,

Aberle,

Birkenfeld

et al. 2024

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

“…Eine Potenzierung von Nebenwirkungen wurde unter oraler Dreifachkombination nicht beobachtet; sie entsprechen im Wesentlichen denjenigen, die bei Monotherapie für die jeweilige Substanz beobachtet werden. Eine neue Option ist die Kombination eines „klassischen“ oralen Antidiabetikums mit Semaglutid oral 75 76 77 78 .…”

Section: Therapieunclassified